Cancer Prevention / Control

  • URCC 10055- Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-treatment, Post-Treatment, and at Six Month Follow-up
  • SWOG S0812- Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
  • ALLIANCE Z11102- Phase II Study of Impact of Breast-Conserving Surgery and Radiotherapy in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
  • GOG 0273- Chemotherapy Toxicity on Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
  • SCUSF 0806 – Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer receiving (Neo) Adjuvant Chemotherapy with Trastuzumab (Herceptin)
  • CALGB 40903- Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS)
  • RTOG 0925- Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Contol In Patients With Supratentorial Low-Risk Grade II Glioma
  • SWOG S0820- A Double Blinded Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage O-III Colon Cancer Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
  • ECOG E1Z11- A Cohort Study to Evaluate Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Women with Stage I-III Breast Cancer(only open to Asian and African-Americans)                                                                                                                   
  • SWOG S1202- Phase III Randomized Placebo-Controlled Study of Duloxetine for Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
  • URCC 13059- A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults
  • URCC 12107- Evaluation of Psychoeducation for Cancer patients Eligible for Clinical Trials